spacer
home > ebr > summer 2017 > hidden treasures
PUBLICATIONS
European Biopharmaceutical Review

Hidden Treasures

Nowadays, both the EMA and FDA want to see treatments based on solid evidence, but how can we document this? For many different diseases, therapeutic effects seem to be poorly defined and challenging to monitor. Fighting a symptom, such as lowering the body’s temperature during a fever, does not count. Truly desirable effects that should be assessed or monitored would include killing bad bacteria in case of an infection, thus lowering the body’s bacterial load.

Usual Matrix Used

Each individual biomarker is part of one or more of seven categories, as defined by the FDA and National Institutes of Health Working Group, including diagnostic, monitoring, prognostic and safety. Biomarkers are endogenous substances, usually easiest to determine in blood plasma, saliva or urine. These bodily fluids are not difficult to obtain and derived from or connected to the bloodstream, which nourishes all organs and is also in contact with the central nervous system and the cerebrospinal fluid. This blood-brain barrier protects our control centre from the detrimental influences of a great number of large molecular substances, which are not able to cross it.

Historically, many may first think of protein biomarkers. Proteins may indeed be closer to the body’s reaction to a disease than small molecules. However, detecting these specific proteins in the blood is not always easy. We have many thousands of proteins in the body which consist of amino acids, and the sequence of the connected amino acids is responsible for the function of the protein.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, founder and Bioanalytical Consultant at pharm-analyt Labor, has more than 100 publications in peer-reviewed journals, including two books by Wiley-VCH. He is also the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases: Gaucher, NPC and metachromatic leukodystrophy.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway1.
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement